Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07569315

Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders

The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Bedaya Hospital

Giza, Egypt

Location contact

Ahmed Gadallah

PRINCIPAL_INVESTIGATOR

Usama M. Fouda, Prof

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • GnRH antagonist IVF cycle
  • Hyper-responders to induction of ovulation

Exclusion criteria

  • Hypogonadotrophic hypogonadism
  • Endometriosis
  • History of recurrent abortion

Treatment and study plan

Successive doses GnRH agonist

Drug

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup. Two additional doses of triptorelin ( 0.1 mg / S.C ) are administered subcutaneously 12 and 24 hours after the first dose of GnRH agonist.

Single dose GnRH agonist

Drug

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.

Primary outcomes

  1. Metaphase-II oocytes rate

    Time frame: Ten to fifteen days after starting ovarian stimulation

    Number of MII oocyte/ number of cumulus oocyte complex

Secondary outcomes

  1. Clinical pregnancy rate

    Time frame: Five weeks after embryo transfer

    Presence of intrauterine gestational sac detected by transvaginal ultrasound

  2. Ongoing pregnancy Rate

    Time frame: Eighteen weeks after embryo transfer

    Pregnancies continued beyond 20 weeks gestation

Study contacts

Contact information is provided by the study sponsor or research team.

Usama M. Fouda, Prof.

CONTACT

[email protected]

+201095401375

Sponsors and collaborators

Lead sponsor

Bedaya Hospital

Other

Registry information

Official study title

Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF Cycle : A Randomized Controlled Study.

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 6, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.